Expression of Prox1 in Medullary Thyroid Carcinoma Is Associated with Chromogranin A and Calcitonin Expression and with Ki67 Proliferative Index, but Not with Prognosis.
Adult
Aged
Calcitonin
/ analysis
Carcinoma, Neuroendocrine
/ genetics
Cell Proliferation
Chromogranin A
/ analysis
Female
Homeodomain Proteins
/ biosynthesis
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Ki-67 Antigen
/ analysis
Male
Middle Aged
Predictive Value of Tests
Prognosis
Survival Analysis
Thyroid Neoplasms
/ genetics
Tumor Suppressor Proteins
/ biosynthesis
Young Adult
CEA
Chromogranin A
Ki67
Medullary thyroid carcinoma
Prognosis
Prox1
Journal
Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
pubmed:
20
4
2019
medline:
31
12
2019
entrez:
20
4
2019
Statut:
ppublish
Résumé
Medullary thyroid carcinoma (MTC) has been shown to express Prospero homeobox protein 1 (Prox1), a transcription factor whose expression is altered in a variety of human cancers. We conducted a retrospective study on a series of 32 patients with MTC to test the correlation of Prox1 expression in MTC with clinicopathological features and to evaluate its prognostic significance. Correlation of Prox1 immunohistochemical expression with tumor size, proliferative index (Ki67), and calcitonin and CEA serum levels prior to surgery was tested for significant correlations. The difference in Prox1 and Ki67 immunohistochemical expression according to the immunohistochemical staining intensity of CEA, chromogranin A, and calcitonin was tested using the Kruskal-Wallis H test and linear regression analysis. The prognostic value of Prox1 and Ki67 for our patient cohort was assessed by Kaplan-Meier log rank survival analysis. We demonstrated a positive correlation between Prox1 expression and Ki67 index. Prox1 also showed significant difference in expression according to chromogranin A and calcitonin immunohistochemical expression, with higher Prox1 expression in tumors with stronger chromogranin A or calcitonin staining. Prox1 expression did not correlate with PFS or OS based on Kaplan-Meier log rank survival analysis. In conclusion, Prox1 expression in MTC is positively correlated with Ki67 and with the immunohistochemical expression of chromogranin A and calcitonin. However, the present study does not support a role for Prox1 in MTC prognosis.
Identifiants
pubmed: 31001799
doi: 10.1007/s12022-019-9576-5
pii: 10.1007/s12022-019-9576-5
doi:
Substances chimiques
CHGA protein, human
0
Chromogranin A
0
Homeodomain Proteins
0
Ki-67 Antigen
0
Tumor Suppressor Proteins
0
prospero-related homeobox 1 protein
0
Calcitonin
9007-12-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-145Références
Nat Genet. 1999 Mar;21(3):318-22
pubmed: 10080188
Cancer. 2000 Mar 1;88(5):1139-48
pubmed: 10699905
EMBO J. 2002 Sep 2;21(17):4593-9
pubmed: 12198161
Mech Dev. 2002 Oct;118(1-2):147-55
pubmed: 12351178
Dev Dyn. 2002 Nov;225(3):351-7
pubmed: 12412020
Nat Genet. 2003 May;34(1):53-8
pubmed: 12692551
Br J Cancer. 2003 Dec 1;89(11):2093-7
pubmed: 14647143
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6005-11
pubmed: 17062673
Dev Dyn. 2007 Feb;236(2):518-24
pubmed: 17117441
BMC Cancer. 2008 Apr 09;8:92
pubmed: 18400094
Cancer Cell. 2008 May;13(5):407-19
pubmed: 18455124
Development. 2009 Feb;136(3):495-505
pubmed: 19091769
J Neuropathol Exp Neurol. 2010 Feb;69(2):129-38
pubmed: 20084020
Am J Surg Pathol. 2010 Jun;34(6):868-72
pubmed: 20463572
Br J Cancer. 2011 Oct 25;105(9):1346-51
pubmed: 21970873
Cancer Metastasis Rev. 2012 Dec;31(3-4):793-805
pubmed: 22733308
Oncologist. 2013;18(10):1093-100
pubmed: 24037980
Cell Rep. 2014 Sep 25;8(6):1943-1956
pubmed: 25242330
Cell Rep. 2014 Sep 25;8(6):1957-1973
pubmed: 25242332
Mol Cancer Ther. 2015 Feb;14(2):499-512
pubmed: 25512616
Oncogene. 2015 Oct 29;34(44):5524-35
pubmed: 25684142
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Virchows Arch. 2015 Sep;467(3):279-84
pubmed: 26063416
Recent Results Cancer Res. 2015;204:61-90
pubmed: 26494384
Cancer Res. 2016 Feb 1;76(3):582-93
pubmed: 26609053
Endocrinology. 2016 Mar;157(3):1289-98
pubmed: 26760117
Onco Targets Ther. 2017 Jul 03;10:3261-3276
pubmed: 28740401
Curr Med Res Opin. 2018 May;34(5):795-803
pubmed: 28812918
Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):335-347
pubmed: 28911729
Sci Rep. 2018 Jun 22;8(1):9531
pubmed: 29934628
Cancer. 1996 Nov 15;78(10):2173-83
pubmed: 8918412
Clin Endocrinol (Oxf). 1998 Mar;48(3):265-73
pubmed: 9578814
Cancer. 1998 Dec 15;83(12):2638-48
pubmed: 9874472